Sonoma Biotherapeutics reports promising early data from phase 1 rheumatoid arthritis trial - PharmaTimes SBT-77-7101 shows favourable safety and early signs of efficacy in patients with refractory RA

#SonomaBiotherapeutics #rheumatoidarthritis #refractoryRA #refractoryrheumatoidarthritis #RegulateRAtrial #RApatients #AmericanCollegeofRheumatology #ACR #clinicalevidence #mechanisticevidence #DAS28CRPscore #CDAIscore #CAR+Tregs #antigendirectedTregs #refractoryRApatients
zurl.co/9fqa2

#autoimmunediseasetreatment #foxp3gene #fredramsdell #immunotherapy #instituteforsystemsbiology #marybrunkow #nobelprize2025 #osakauniversity #peripheralimmunetolerance #regulatorytcells #shimonsakaguchi #sonomabiotherapeutics